multiple sclerosis

#Ocrelizumab – How Ocrelizumab Works

Ocrelizumab, an anti-CD20 monoclonal antibody, targets mature B-cells. Almost 95% of the B-cell population has these antigenic epitopes after maturation and does not shed them, which is what makes it a potent marker for therapeutic purposes (cancer being a very common area of interest in this regard). Read more…

Does Sun Exposure in Early Years Delay MS Onset?

Exposure to sunlight may delay the development of multiple sclerosis (MS), according to a new study from researchers in Denmark. The work, titled “Association between age at onset of multiple sclerosis and vitamin D levelā€“related factors,” appeared October 7, 2015 in the journal Neurology.

Biomarkers and Predictors For Developing Future Personalized MS Therapies Discussed at ECTRIMS 2015

New developments in the diagnosis and treatment of multiple sclerosis (MS) are being discussed at this year’sĀ 31st annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). TheĀ symposium, being held in Barcelona, Spain, will fosterĀ discussions about development of individualized therapiesĀ forĀ MS patients throughĀ a more targeted and efficient…

PCORI Board Approves $83 Million for Research on Multiple Sclerosis, Hepatitis C and Rare Diseases

The Patient-Centered Outcomes Research Institute (PCORI) Board of Governors recently approvedĀ an $83 million grant to support 26 patient-centered, comparative effectiveness clinical research (CER) studies on a range of diseases and patient groups. Two of these grants, totaling $29.5 million, will fund research intoĀ the care of patients infected with hepatitis…

Kessler Foundation Researchers Report BICAMS Can Predict Performance of Everyday Life Activities in Multiple Sclerosis Patients

Kessler Foundation researchers recently reported that the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) is able to predict the performance of normal daily activities. According to the researchers, the BICAMS is a promising tool to predict actual functional performance in participants with multiple sclerosis (MS). MS is a progressive…

Fingolimod (Gilenya) Found to Be an Effective Multiple Sclerosis Therapy for Up to Three Years of Treatment

An encouraging newĀ analysis reveals that fingolimod isĀ an effective multiple sclerosis (MS) therapy forĀ a treatment period of up to three years. The results were presented at the Annual Meeting of the Consortium of MS Centers. MS is a chronic, progressive neurodegenerative disorder that is the result ofĀ anĀ attack onĀ the central nervous system…

New Genetic Risk Factors for Multiple Sclerosis Identified in Study

Two new risk factors for multiple sclerosis have been identified by a research group at the Wellcome Trust Centre for Human Genetics at the University of Oxford in the United Kingdom. Led by Dr. Loukas Moutsianas, the team discovered that having HLA-DQA1*01:01ā€“HLA-DRB1*15:01 and HLA-DQB1*03:01ā€“HLA-DQB1*03:02 gene allele…

Biomarkers of Early MS and Overactive Bladder Identified in New Study

Researchers at theĀ University of Athens Medical School in GreeceĀ have found that people with early stage multiple sclerosis (MS) and overactive bladderĀ (OAB) have reductions in brain serotoninĀ and a stress-related hormone, cortisol. Serotonin is a chemical that helps nerve cells to communicate. The study, titled “Neurochemical and…

Could Salt Intake be an MS Risk Factor?

Most people know that eating too much salt is bad for your health, but a new study suggests that it could also increase the risk for multiple sclerosis (MS). The workĀ appearedĀ in the August 2015 issue of The FASEB Journal,Ā the journal of the FederationĀ of…

MS Views and News Announces August Educational Events

The non-profit organization MSĀ News and ViewsĀ (MSVN) announced that it will host four educational events during the month of August for both patients and other peopleĀ interested in learning more aboutĀ multiple sclerosis (MS). The educational events reflectĀ the organization’s ongoing mission, which is to collect, present and…

Report Shows MS Patients Miss Out On Access To Palliative Care Services

A recentĀ report by Marie Curie fellows organization suggests that those suffering fromĀ neurological conditions such as multiple sclerosisĀ are missing out on care that couldĀ make a major difference inĀ the quality of their lives. When it comes to palliative care, the report contends thatĀ there is a limited understanding about the need…

LMU Researchers Identify Biomarker BCMA to Measure MS Severity

In a recent study published in the journal Nature Communications, LMU clinicians have clarified the lifespanĀ of antibody-producing cells and have also identified a novel biomarker that could be used to monitor autoimmune conditions such as multiple sclerosis and lupus erythematous. The humoral immune response is mediated byĀ cells…